retatrutide triple agonist clinical trial Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide for weight loss: Study

The robust triglyceride reduction seen at higher retatrutide doses is attributed to the glucagon receptor pathways direct stimulation of hepatic fat oxidation, which reduces hepatic VLDL secretion and subsequently lowers circulating triglyceride concentrations

For others, nausea shows up later, often the next day

82,83 Animal studies have demonstrated the protective effects of DPP4 inhibitors in IBD

However, excessive length may impede ligand to bind and activate receptor

02.01.23 FDA investigates promotional TV segment The FDA announced it was investigating claims that Novo Nordisk paid for a promotional segment, appearing to be a news segment on the CBS program 60 Minutes

Semaglutide reduces major adverse cardiovascular events, heart failure composite, cardiovascular death, and all-cause death in patients with atherosclerotic cardiovascular disease and overweight or obesity and heart failure